The hallmark features are thrombocytopenia, thrombosis within 5–30 days of adenoviral SARS-CoV-2 vaccination, with strikingly elevated levels of D-dimer, hypofibrinogenemia, and positive antibodies against platelet factor 4 (PF4) (2). This evidence concerns the gene PF4 and Hypofibrinogenemia.